Zimberelimab

Immune checkpoint inhibitors, including those targeting the programmed cell death protein 1 receptor (PD-1) and ligand (PD-L1), have shown promise in the treatment of advanced, relapsed and refractory solid tumors. Zimberelimab (also known as AB-122 or GLS-010) is a fully human immunoglobulin G4 monoclonal antibody against the PD-1 receptor being developed by Arcus Biosciences (AB-122) and Harbin Gloria Pharmaceuticals (GLS-010) for the treatment of advanced solid tumor cancers. Preclinical investigations show zimberelimab has a similar activity and selectivity profile to currently approved PD-1 inhibitors. Early data from phase I studies show similar rates of treatment-related adverse events and suggest particular benefit in tumors with PD-L1 and tumor mutation burden (TMB) biomarker positivity. Many early phase clinical trials are investigating its safety and efficacy in a variety of regimens, including as monotherapy, in combination with standard chemotherapies, and in combination with other immunotherapeutic agents targeting the tumor microenvironment.

Automated summary

Immune checkpoint inhibitors, such as Zimberelimab, have shown potential in the treatment of solid tumors. Zimberelimab exhibits similar activity and selectivity to currently approved PD-1 inhibitors and shows particular benefit in tumors with PD-L1 and TMB positivity. Various early phase clinical trials are investigating its safety and efficacy in different treatment regimens.